CoChat

CSF1-ETS2-induced microRNA in myeloid cells promote metastatic tumor growth

Open access
Mathsyaraja, H, Thies, K, Taffany, D A, Deighan, C, Liu, T, Yu, L, Fernandez, S A, Shapiro, C, Otero, J, Timmers, C, Lustberg, M B, Chalmers, J, Leone, G, Ostrowski, M C · 2015 · Oncogene
Cited by 65

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Metastasis of solid tumors is associated with poor prognosis and bleak survival rates. Tumor-infiltrating myeloid cells (TIMs) are known to promote metastasis, but the mechanisms underlying their collaboration with tumor cells remain unknown. Here, we report an oncogenic role for microRNA (miR) in driving M2 reprogramming in TIMs, characterized by the acquisition of pro-tumor and pro-angiogenic properties. The expression of miR-21, miR-29a, miR-142-3p and miR-223 increased in myeloid cells during tumor progression in mouse models of breast cancer and melanoma metastasis. Further, we show that these miRs are regulated by the CSF1-ETS2 pathway in macrophages. A loss-of-function approach utilizing selective depletion of the miR-processing enzyme Dicer in mature myeloid cells blocks angiogenesis and metastatic tumor growth. Ectopic expression of miR-21 and miR-29a promotes angiogenesis and tumor cell proliferation through the downregulation of anti-angiogenic genes such as Col4a2, Spry1 and Timp3, whereas knockdown of the miRs impedes these processes. miR-21 and miR-29a are expressed in Csf1r+ myeloid cells associated with human metastatic breast cancer, and levels of these miRs in CD115+ non-classical monocytes correlates with metastatic tumor burden in patients. Taken together, our results suggest that miR-21 and miR-29a are essential for the pro-tumor functions of myeloid cells and the CSF1-ETS2 pathway upstream of the miRs serves as an attractive therapeutic target for the inhibition of M2 remodeling of macrophages during malignancy. In addition, miR-21 and miR-29a in circulating myeloid cells may potentially serve as biomarkers to measure therapeutic efficacy of targeted therapies for CSF1 signaling.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/onc.2014.294

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 65

Metadata

Authors
Mathsyaraja, H., Thies, K., Taffany, D. A., Deighan, C., Liu, T., Yu, L., Fernandez, S. A., Shapiro, C., Otero, J., Timmers, C., Lustberg, M. B., Chalmers, J., Leone, G., & Ostrowski, M. C.
Venue
Oncogene
Published
2014-09-22
Volume
34
Issue
28
Pages
3651-3661
ISSN
  • 0950-9232 (ISSN-L)
  • 1476-5594
OpenAlex
W2000830882
Cited by
65
References
12
FWCI
2.33
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CSF1-ETS2-induced microRNA in myeloid cells promote metastatic tumor growth. https://app.cochat.ai/papers/10.1038/onc.2014.294
The paper
Mathsyaraja, H., Thies, K., Taffany, D. A., Deighan, C., Liu, T., Yu, L., Fernandez, S. A., Shapiro, C., Otero, J., Timmers, C., Lustberg, M. B., Chalmers, J., Leone, G., & Ostrowski, M. C. (2015). CSF1-ETS2-induced microRNA in myeloid cells promote metastatic tumor growth. Oncogene. https://doi.org/10.1038/onc.2014.294

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.